These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27036962)

  • 1. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
    Sabin CA; Reiss P; Ryom L; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; de Wit S; Smith C; Dabis F; d'Arminio Monforte A; El-Sadr W; Lundgren JD;
    BMC Med; 2016 Mar; 14():61. PubMed ID: 27036962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir use and risk of recurrent myocardial infarction.
    Sabin CA; Ryom L; d'Arminio Monforte A; Hatleberg CI; Pradier C; El-Sadr W; Kirk O; Weber R; Phillips AN; Mocroft A; Bonnet F; Law M; de Wit S; Reiss P; Lundgren JD;
    AIDS; 2018 Jan; 32(1):79-88. PubMed ID: 29028664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.
    Antoniou T; Gillis J; Loutfy MR; Cooper C; Hogg RS; Klein MB; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Raboud JM;
    J Int Assoc Provid AIDS Care; 2014; 13(2):153-9. PubMed ID: 23887923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
    Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
    Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.
    Elion RA; Althoff KN; Zhang J; Moore RD; Gange SJ; Kitahata MM; Crane HM; Drozd DR; Stein JH; Klein MB; Eron JJ; Silverberg MJ; Mathews WC; Justice AC; Sterling TR; Rabkin CS; Mayor AM; Klein DB; Horberg MA; Bosch RJ; Eyawo O; Palella FJ;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):62-72. PubMed ID: 29419568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
    Brothers CH; Hernandez JE; Cutrell AG; Curtis L; Ait-Khaled M; Bowlin SJ; Hughes SH; Yeo JM; Lapierre DH
    J Acquir Immune Defic Syndr; 2009 May; 51(1):20-8. PubMed ID: 19282778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.
    Ding X; Andraca-Carrera E; Cooper C; Miele P; Kornegay C; Soukup M; Marcus KA
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):441-7. PubMed ID: 22932321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV.
    Jaschinski N; Greenberg L; Neesgaard B; Miró JM; Grabmeier-Pfistershammer K; Wandeler G; Smith C; De Wit S; Wit F; Pelchen-Matthews A; Mussini C; Castagna A; Pradier C; d'Arminio Monforte A; Vehreschild J; Sönnerborg A; Anne AV; Carr A; Bansi-Matharu L; Lundgren J; Garges H; Rogatto F; Zangerle R; Günthard HF; Rasmussen LD; Nescoi C; Van Der Valk M; Menozzi M; Muccini C; Mocroft A; Peters L; Ryom L;
    AIDS; 2023 Mar; 37(3):467-475. PubMed ID: 36001525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
    Wohl DA; Arnoczy G; Fichtenbaum CJ; Campbell T; Taiwo B; Hicks C; McComsey GA; Koletar S; Sax P; Tebas P; Ha B; Massengale K; Walsh K; Stein JH
    Antivir Ther; 2014; 19(2):141-7. PubMed ID: 23985706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
    Dorjee K; Choden T; Baxi SM; Steinmaus C; Reingold AL
    Int J Antimicrob Agents; 2018 Nov; 52(5):541-553. PubMed ID: 30040992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
    Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
    J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
    Young J; Xiao Y; Moodie EE; Abrahamowicz M; Klein MB; Bernasconi E; Schmid P; Calmy A; Cavassini M; Cusini A; Weber R; Bucher HC;
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):413-21. PubMed ID: 25932884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.
    Marcus JL; Neugebauer RS; Leyden WA; Chao CR; Xu L; Quesenberry CP; Klein DB; Towner WJ; Horberg MA; Silverberg MJ
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):413-9. PubMed ID: 26536316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.